Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK249320A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving GSK249320A | EXPERIMENTAL | Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1. |
| Subjects receiving placebo | PLACEBO_COMPARATOR | Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1. |
| Name | Type | Description |
|---|---|---|
| GSK249320A | DRUG | GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump. |
| Placebo | DRUG | Sodium chloride intravenous infusion will be given as matching placebo. |
Inclusion Criteria: * Healthy adult men or women of non-child bearing potential (i.e. post-menopausal or surgically sterile e.g. hysterectomy or bilateral oophorectomy). If necessary, postmenopausal status will be confirmed by serum FSH and oestradiol concentrations at screening. Surgical sterility...
GSK249320A is an investigational small molecule being studied for the treatment of Cerebrovascular Accident, commonly known as stroke. It is in Phase 1 clinical development and is not yet approved for any use. The drug is being developed by GSK plc.
The molecular target of GSK249320A has not been disclosed in available information. As a small molecule in early development for Cerebrovascular Accident, its specific mechanism of action is not publicly detailed. The drug is being evaluated in clinical trials to determine its safety and potential efficacy.
GSK249320A is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and tolerability in patients with Cerebrovascular Accident.
GSK249320A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in early-stage trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and patients.
GSK249320A has one completed Phase 1 clinical trial registered as NCT00622609, titled 'Anti-MAG First Administration to Human'. This trial enrolled 46 participants, including healthy volunteers, and was conducted in the United States and Australia. The study was placebo-controlled and randomized.
GSK249320A is associated with the trial title 'Anti-MAG First Administration to Human', but this is a descriptive name for the study, not an alternative drug name. The drug is primarily known as GSK249320A in clinical development records.